The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety

BACKGROUND: The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivity of thiazolidinediones for peroxisome proliferator-activated receptors in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Leonard, Charles E., Brensinger, Colleen M., Dawwas, Ghadeer K., Deo, Rajat, Bilker, Warren B., Soprano, Samantha E., Dhopeshwarkar, Neil, Flory, James H., Bloomgarden, Zachary T., Gagne, Joshua J., Aquilante, Christina L., Kimmel, Stephen E., Hennessy, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041286/
https://www.ncbi.nlm.nih.gov/pubmed/32098624
http://dx.doi.org/10.1186/s12933-020-00999-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7041286/
https://www.ncbi.nlm.nih.gov/pubmed/32098624
http://dx.doi.org/10.1186/s12933-020-00999-5

Ejemplares similares